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ABSTRACT
Objectives: Endometrial thickness of <9 mm is a predictor of in vitro fertilization (IVF) failure, although neither pregnancy rates nor the pregnancy 
outcomes are dependent on the endometrial thickness alone. The impact that uterine artery blood flow has on endometrial growth is dependent on 
nitric oxide which concentrations could be altered by halting a cyclic guanosine monophosphate-mediated pathway with a phosphodiesterase type 5 
selective inhibitor such as sildenafil.
Methods: In this clinical trial, 72 patients aged below 45 years which have had at least two earlier failed IVF attempts were randomly split into 
two groups each consisting of 36 patients. Both groups were started on a long IVF protocol. The case group was also administered 100 mg vaginal 
sildenafil suppositories daily, starting on day 3 of menstruation which was continued until human chorionic gonadotropin administration. Endometrial 
thickness was measured using ultrasonography in both groups plus pregnancy rates were assessed in both groups.
Results: The mean age of the patients in Group A who received sildenafil was 33.8±4.8 in contrast to Group B (control group) with the mean age of 
33.8±4.8. Mean endometrial thickness of 8.6±0.1 mm was recorded in Group B compared to 9.0±0.7 mm in Group A (p=0.03). Of all the 36 participants 
who received sildenafil citrate during the IVF cycle, 12 (33.3%) patients had successful pregnancies while 24 (66.7%) failed to get pregnant. In the 
control group, out of the 36 participants, 10 (27.8%) patients got pregnant while 26 (72.2%) failed the cycle (p=0.9).
Conclusion: This study showed that although using vaginal sildenafil during the IVF cycle does improve endometrial thickness before implantation, 
this does not necessarily lead to higher pregnancy rates.
Keywords: Infertility, Sildenafil, In vitro fertilization.
INTRODUCTION
Infertility is defined as incapability to conceive despite having regular 
unprotected sex for at least a year [1,2]. Around one in six or seven 
couples may have difficulty getting pregnant. Unexplained infertility in 
addition to common causes of infertility such as ovulation problems, 
tubal blockage, male associated infertility, uterine problems, and 
infections are causes which could eventually lead to using associated 
reproductive technology commonly known as ART in the treatment 
of infertility [3-6]. In vitro fertilization (IVF) as a helpful way to treat 
infertility, particularly fallopian tube and ovarian-related infertility, 
may lead to failure due to many factors such as female age, embryo 
quality, ovarian response, or implantation issues. Endometrial 
thickness of <9 mm has been long known to be a predictor of IVF 
failure, although neither pregnancy rates nor the pregnancy outcome is 
dependent on the endometrial thickness alone [7]. A thin endometrial 
lining may mirror previous or a current uterine pathology, and with the 
importance that uterine artery blood flow has on endometrial growth, 
we could conclude that improving uterine blood flow may facilitate 
achieving higher pregnancy rates. The significance of nitric oxide 
(NO) as a modulator of uterine blood flow through the relaxation of 
vascular smooth muscle by a cyclic guanosine monophosphate (cGMP)-
mediated pathway has been studied [8]. Phosphodiesterase (PDE) 
enzymes also play a role in the NO-CGMP cycle by hydrolyzing cGMP 
through degrading the phosphodiester bond in these second messenger 
molecules and so regulating the signal transduction mediated by cGMP. 
PDE inhibitors (PDE I) can prevent this degrading of cGMP molecules by 
inhibiting the PDE enzyme.
Sildenafil (Viagra) is a PDE type 5 selective inhibitor, which facilitates 
the vasodilatory effects of cGMP in the corpus cavernosum and is used 
to treat erectile dysfunction, as well as having some other medical 
applications such as treatment of pulmonary hypertension [9,10]. 
METHODS
Following approval of the Ethics Committee of Tehran University 
of Medical Sciences, with the aim of evaluating the effect of vaginal 
sildenafil suppositories on endometrial thickness and IVF success rate, 
a total number of 72 subjects were selected from the patients who were 
referred to Emam Hospital over a period of 7 months.
The following inclusion criteria were applied for selecting the patients 
eligible to take part in this study:
Women who had previously at least two IVF failure attempts and 
women aged below 45 years of age. 
Patients are 45 years of age or older and patients with a history of heart 
failure (function class III or higher), signs of severe or chronic ischemia 
of the lower extremities, or pulselessness on physical examination, 
a previously diagnosed hematological, renal, hepatic or endocrinal 
disorder, medical history of acute/chronic heart disease, or high blood 
pressure were not included in the study.
The patients should also be mentally intact to be able to give a written 
form of consent. After the patients had been selected to enroll in the 
study, all participants were fully informed of the nature of the study 
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and provided a written informed consent. In the primary assessment, 
a detailed medical history was taken which stressed on duration since 
the 1st time diagnosis of infertility, previous IVF attempts, previous 
treatments used, and allergies to any drugs. The patients were 
randomly divided into two groups. In both groups, on day 21 of the 
previous cycle, patients were admitted to the hospital and were injected 
subcutaneously 3 times a day at 8 h intervals of 0.5 mL Suprefact 
(Category A: 21.10: Trophic hormones), for 7 days. Each 1 mL of the 
aqueous solution contains 1.05 mg buserelin acetate corresponding 
to 1 mg buserelin base as the active ingredient. On day 3 of menstrual 
cycle, Gonal-F was started in both groups. Daily 100 mg vaginal 
sildenafil suppositories were also administered to the patients in the 
case group from the 3rd day of menstruation which was continued until 
to the date of human chorionic gonadotropin (HCG) administration. 
Endometrial thickness in both groups was measured by a previously 
trained physician. All the patients were followed by clinical pregnancy 
or failure was recorded. Statistical analysis of the results was performed 
using SPSS for windows version 11.5, and data are presented as means 
± standard deviation. Independent paired t-test was performed for the 
comparison of the case group who received vaginal sildenafil and the 
control group. p<0.05 was statistically considered significant.
RESULTS
Basic characteristics
A total number of 72 patients aged between 21 and 43 years who were 
compliant with the inclusion and exclusion criteria were enrolled in this 
study. The mean age of the patients in Group A who received sildenafil 
(case group) was 33.8±4.8 in contrast to Group B (control group) with 
the mean age of 33.8±4.8.
The mean duration of previously diagnosed infertility before treatment 
in Group A and B was 10.3 and 10.1 of years. The mean number of 
ova conceived during the IVF cycle in Group A was 9.6±5.9, and in the 
control group, the mean number of ova’s conceived was 9.3±6.
Mean number of embryos transferred in the case group was 2.8±2.0 in 
contrast to 2.8±0.8 in the control group.
Adverse drug effects
During the IVF cycle, the patients were evaluated for any adverse drug 
reactions to sildenafil through physical examinations, but no clinically 
significant side effects were observed and all the patients tolerated the 
drug during the treatment.
Endometrial thicknesses and pregnancy
The 36 patients in Group B (control group) who did not receive the 
drug were undergone vaginal sonography with the mean endometrial 
thickness of 8.6±0.1 mm. All the patients who were randomly chosen to 
be in Group A (case group) and received sildenafil suppositories were 
also undergone vaginal sonography. The mean endometrial thickness 
in Group A was 9.0±0.7 mm which were statistically significant 
compared to the endometrial thickness in Group B (p=0.03). Of all the 
36 participants who received sildenafil citrate during their IVF cycle, 12 
(33.3%) patients had successful pregnancies while 24 (66.7%) failed to 
get pregnant. In the control group, out of the 36 participants, 10 (27.8%) 
patients got pregnant while 26 (72.2%) failed the cycle (p=0.9).
DISCUSSION
The fact that better endometrial thickness could help achieve higher 
pregnancy rates is understandable and has been made known [11], the 
hypothesis that vaginal sildenafil could directly increase clinical pregnancy 
rates, although previously studied has not been well established.
Vaginal sildenafil has been shown to have favorable effects on 
endometrial thickening as it is observed in previous studies [12,13]. 
In this study, we showed that using vaginal sildenafil during the IVF 
cycle does improve endometrial thickness, although there have been 
contraindicating results in other studies too.
Endometrial thickening is most probably the result of sildenafil acting 
as a PDE type 5 selective inhibitor, which helps accumulate NO through 
a cGMP pathway resulting in better blood flow.
Although higher concentrations of NO could result in better blood 
flow in the uterine, based on previous studies conducted on mice, it 
could also inhibit both embryo development in vitro and implantation 
in vivo [14], which is why discontinuing sildenafil administration before 
the date of HCG administration was proposed by Sher et al. [12]. It has 
also been proposed that the GMP pathway might be involved in the NO-
regulated embryonic development, but not in NO-induced apoptosis 
which could lead to errors during implantation.
Although no specific side effects or toxicity was observed in our study, 
with the fact that NO has important roles during embryo development 
and using sildenafil citrate during the IVF cycle, the NO concentrations 
are altered more studies are needed to verify the safety of vaginal 
sildenafil on the babies.
In cases where infertility is specifically related to a deficiency in blood 
flow such as Asherman’s syndrome, treatment cycle with vaginal 
sildenafil citrate is effective [15]. In a retrospective cohort analysis of 
105 infertile women aged <40 years, with at least two consecutive prior 
IVF failures attributed to inadequate endometrial development Sher 
et al. expressed that sildenafil citrate could enhance the endometrium 
development although they did not clearly evaluate the difference in the 
pregnancy rates [13].
From the results of this study, it may be concluded that although using 
vaginal sildenafil during the IVF cycle does improve endometrial 
thickness before implantation, this does not mean that higher 
pregnancy rates that are statistically significant will be achieved which 
highlights other roles that NO could have during the process apart from 
muscle relaxation and increase blood flow.
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